Newsfeeds - Spark Newswire

2 minute read

PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson’s Disease

Today, 7:58 AM

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at the MDS

CSE:PHRM

2 minute read

Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies

By Lara Goldstein

Today, 7:58 AM

PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs.

PHRRF

3 minute read

PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson’s And Motor Disorders Treatment

By Lara Goldstein

Today, 7:58 AM

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S.

PHRRF

3 minute read

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry

By Natan Ponieman

Today, 7:58 AM

In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its success on the regulation and approval of scheduled psychoactive substances for mental health and other health indications.

ATAI

1 minute read

Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process

By Fermin Orgambide

Today, 7:58 AM

The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process.

PHRRF

5 minute read

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward

By Natan Ponieman

Today, 7:58 AM

The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.

ATAI

2 minute read

Ketamine Could Help Treat Parkinson’s Disease, Study Finds

By Benzinga Newsdesk

Today, 7:58 AM

PharmaTher Holdings Ltd. (OTCQB:PHRRF) announced positive results from a clinical study of ketamine for the treatment of levodopa-induced…

PHRRF

6 minute read

Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022

By Microdose Psychedelic Insights

Today, 7:58 AM

This article was originally published on Microdose and appears here with permission.

CSE:PHRM

2 minute read

FDA Approves PharmaTher’s Phase 2 Trial For Ketamine ALS Treatment

By Aaron Bry

Today, 7:58 AM

PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S.

CSE:PHRM